{'fraction_non_alphanumeric': 0.03414634146341464, 'fraction_numerical': 0.024390243902439025, 'mean_word_length': 5.16, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Current problems of hepatitis C virus infection in hemodialysis patients.

Hepatitis C virus (HCV) accounts for the majority of cases of non-A, non-B hepatitis. Chronic infection develops in at least 70%of infected patients and progresses to cirrhosis and hepatocellular carcinoma in approximately 20%. Confirmatory assays for circulating antibodies to HCV(anti-HCV) were developed soon after the molecular cloning of HCVin 1989 (1). The first generation assay included only the nonstructural protein 4 (NS4 or C100-3) antigens. This assay was not complete due to its low sensitivity, especially in the screening of